Meet Diadem at
JPM Healthcare Conference 2025
January 12-16, San Francisco, The Westin St. Francis
Join us to explore how Diadem is transforming Alzheimer's Disease
ALZOSURE TEST
Our test is a plasma-based and capable of identifying a particular status of P53 which demonstrated to be highly sensitive and specific for Alzheimer’s Disease. Alzosure also proved to be accurate for beta amyloid (ẞ Amyloid PET), the standard of care biomarker in diagnosis of Alzheimer’s disease
Bill Gates
“There’s still no cheap, effective way to diagnose the disease.”
Prof. Reisa Sperling, Harvard University
On how to make Alzheimer’s trials work: “..when you’re going after this amyloid plaque buildup you need to start 10 years before”
Patient’s experience; Voices of Alzheimer’s Disease – Alzheimer’s association; 2008
“My diagnosis took eight months. […] I went through a battery – neuropsych testing, spinal taps, MRIs, blood work – you name it and I went through it.”
Voices of Alzheimer’s Disease – Alzheimer’s association; 2008
“In this bright age of science, we still don’t have a defining way of making a diagnosis early that says, This is Alzheimer’s, and let’s cope with it.”
ABOUT DIADEM
Our Mission
is to enable prediction, monitoring, diagnosis & successful drug development for Alzheimer’s disease. Diadem is determined to solve one of the biggest problems in Alzheimer’s disease drug development and patient care: early, accurate, predictive, fast, non-invasive and cost effective diagnosis.
Diadem
Diadem is a pure diagnostic company committed to carry on specific research and development on early peripheral markers of Alzheimer’s disease into technology, bringing together some of the most senior experts from industry and academia to advance a breakthrough in Alzheimer’s disease in the clinic. Diadem is preparing for large retrospective and prospective trials to confirm initial data
The Product
is an innovative blood-based test exploiting a proprietary antibody targeting a specific conformation of p53 protein. This biomarker, known to be associated with several patients’ inflammatory conditions is highly specific for Alzheimer’s Disease onset. In pilot clinical studies, the test shows the ability to predict the risk of cognitive decline in patients who are being assessed for Alzheimer’s Disease. AlzoSure™ is also an enabler of effective patient’s recruitment in clinical trials for the development of AD drugs.